drugset / Trial / NCT00496847

Efficacy and Safety of PERIOGEN in the Treatment of Periodontal Bone Defect

NCT00496847 ↗

Phase 3 Completed 60 enrolled Virchow Group
RandomizedParallel-groupDouble-blindTreatment

Summary

PERIOGEN, containing rhPDGF and -beta-TCP, promotes gingival healing and corrects periodontal defects. This study will test the safety and efficacy of PERIOGEN in the treatment of periodontal disease

Timeline

Start
2007-08
Primary completion
2008-08
Completion
2009-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Beta TCP Other / unclassified 0.5 g Other
Comparator Beta TCP Other / unclassified 0.5 g Other
Subject rhPDGF-BB Protein / enzyme biologic 0.3 mg/ml Other

Indications